Done ADHD Pricing Analysis & Total Cost: Is It Worth It in 2025?

What Done Actually Charges: A Full Cost Breakdown

Done markets a simple membership model, but the number on the homepage is not the number you pay at the end of the year. The first-month fee covers an intake evaluation with a licensed clinician (typically a nurse practitioner or physician assistant), and subsequent months cover medication-management visits and messaging. Medication itself is a separate transaction at the pharmacy.

Membership Fee Structure

The published fee structure as of mid-2025 is:

| Period | Reported Cost | |---|---| | Month 1 (evaluation + first Rx) | ~$199 | | Months 2+ (ongoing management) | ~$79, $99/month | | Estimated annual total (membership only) | ~$1,067, $1,388 |

These figures are cash-pay. Done does not bill insurance directly for most plans, though some patients have successfully submitted for out-of-network reimbursement. The platform itself has stated this on its site, and independent patient-community reporting on Reddit's r/ADHD and r/Telehealth threads is broadly consistent with these ranges.

What You Still Owe at the Pharmacy

A Done membership does not cover medication. Stimulant medications prescribed for ADHD range widely in cost:

• Generic amphetamine salts (Adderall generic, 30-count): $30, $60 with GoodRx at major chains
• Brand Adderall (30-count): $200, $400 without insurance
• Generic mixed amphetamine salts XR: $60, $120 with coupons
• Vyvanse (lisdexamfetamine) brand: $350, $400/month without coverage; generic became available in 2023 and runs $60, $100 with coupons

A patient on a generic stimulant using GoodRx might spend $40, $60/month on medication, bringing the true monthly cost to $120, $160 in months 2+. A patient who needs brand-name Vyvanse without insurance faces $430, $500/month in combined membership and medication costs.

Hidden Cost: Shortage-Related Disruptions

The U.S. Has experienced an ongoing amphetamine shortage since late 2022. The FDA maintains a drug shortage database, and as of 2025 mixed amphetamine salts remain intermittently listed [1]. When a pharmacy cannot fill a controlled stimulant, Done cannot ship or transfer a backup. Patients report paying for membership months during which they could not obtain their medication. That represents a real financial loss.

Is Done Legit? Licensing, DEA Rules, and Clinical Standards

Done operates as a legitimate telehealth company in the sense that it employs state-licensed clinicians and issues prescriptions through legal channels. The more precise question is whether its clinical model meets the standard of care for ADHD diagnosis and management.

Clinician Credentials and State Licensing

Done uses nurse practitioners and physician assistants as prescribers in most states. Both credential types are legally authorized to diagnose and prescribe in the states where Done operates. The American Academy of Family Physicians recognizes telehealth as a valid care delivery format for ADHD management when appropriate assessment tools are used [2].

The DEA Telemedicine Prescribing Question

This is where Done's model carries real regulatory risk for patients. Under the Ryan Haight Act, prescribing Schedule II controlled substances (which includes amphetamines and methylphenidate) via telemedicine ordinarily requires an in-person evaluation first. During the COVID-19 public health emergency, the DEA issued a blanket waiver allowing telehealth-only controlled-substance prescribing. That waiver expired, and the DEA has been working through proposed rules for a permanent telemedicine prescribing framework since 2023 [3].

As of mid-2025, the DEA's special-registration framework for telemedicine prescribing of controlled substances remains in a regulatory transition period. Done and similar platforms are operating under extended pandemic-era flexibility while permanent rules are finalized. Patients should check the current DEA guidance before starting, because a rule change could require an in-person visit to continue prescriptions.

Diagnostic Quality

Done uses a digital intake questionnaire based loosely on ADHD rating scales such as the Adult ADHD Self-Report Scale (ASRS-v1.1), a validated 6-item screen developed for the World Health Organization [4]. The ASRS-v1.1 has a sensitivity of approximately 68.7% and specificity of 99.5% for identifying DSM-IV ADHD in primary care samples [4]. Using a screen alone, without a structured clinical interview, neuropsychological testing, or collateral history, is not considered a full diagnostic evaluation by the American Psychiatric Association's practice guidelines [5].

The HealthRX clinical team uses a 3-tier ADHD telehealth quality framework when evaluating platforms:

• Tier 1 (screening-only): digital questionnaire, no structured interview. Adequate for identifying likely cases; insufficient for a formal DSM-5 diagnosis.
• Tier 2 (structured interview): clinician conducts a live clinical interview using validated criteria. Meets minimum guideline standards.
• Tier 3 (comprehensive): structured interview plus collateral history (school records, partner/parent report), neuropsychological screening where indicated. Recommended for complex or ambiguous cases.

Done's standard intake falls in Tier 1 to Tier 2, depending on the clinician. Patients with complex presentations (comorbid anxiety, prior trauma, suspected learning disabilities) may receive an inadequate evaluation.

What Done Prescribes: Medication Options and Limitations

Done prescribes FDA-approved stimulant and non-stimulant medications for ADHD. The specific agents available depend on your state, the prescriber's judgment, and current supply.

Stimulant Options

Common stimulants reported by Done patients include:

• Mixed amphetamine salts (generic Adderall, immediate-release)
• Mixed amphetamine salts XR (generic Adderall XR)
• Lisdexamfetamine (Vyvanse), brand and now generic
• Methylphenidate (generic Ritalin, various formulations)

All of the above are DEA Schedule II. Done cannot call in a refill; each month requires a new written/electronic prescription, which is standard for Schedule II medications under federal law.

Non-Stimulant Options

For patients who cannot tolerate or do not respond to stimulants, Done clinicians may prescribe:

• Atomoxetine (Strattera generic): a norepinephrine reuptake inhibitor; FDA-approved for ADHD in adults; not a controlled substance, so easier to prescribe via telehealth
• Viloxazine (Qelbree): FDA-approved for adults with ADHD as of April 2021 [6]; non-controlled
• Guanfacine ER or clonidine ER: off-label in adults, Schedule IV or non-controlled

Non-stimulant options have lower efficacy on average. A 2018 meta-analysis in The Lancet Psychiatry (N=52 comparator arms, 10,068 participants) ranked methylphenidate and amphetamines as the most effective agents in adults, with atomoxetine producing smaller effect sizes [7].

What Done Does Not Prescribe

Done does not manage psychiatric comorbidities such as bipolar disorder, schizophrenia, or active suicidality. If a clinician identifies these during intake, they refer out. The platform is intentionally narrow.

Done vs. Alternatives: Cost and Quality Comparison

Several telehealth platforms compete directly with Done in the ADHD space. The table below compares the major options across pricing, prescribing model, and clinical depth.

| Platform | Initial Fee | Ongoing Fee | Insurance Billed? | Controlled Substances? | Diagnostic Depth | |---|---|---|---|---|---| | Done | ~$199 | ~$79, $99/mo | No (some OON) | Yes (stimulants) | Tier 1 to 2 | | Cerebral | ~$85, $99/mo | ~$85, $99/mo | Yes (some plans) | Varies by state | Tier 2 | | Ahead | ~$199 | ~$99/mo | No | Yes | Tier 1 to 2 | | Talkiatry | Varies | ~$30, $50 copay | Yes (in-network) | Yes | Tier 2 to 3 | | Traditional psychiatrist (in-person) | ~$300, $500 | ~$150, $300/visit | Yes (most plans) | Yes | Tier 3 | | Primary care physician (in-person) | Copay | Copay | Yes | Yes | Tier 1 to 2 |

Cerebral faced significant FTC and DEA scrutiny in 2022 to 2023 over prescribing practices, resulting in a $10 million FTC settlement in 2023 [8]. Done has not faced equivalent federal enforcement actions as of this writing, but the regulatory environment for all ADHD telehealth platforms remains heightened.

When Done Is Cheaper Than the Alternative

For a patient who has no insurance, lives in a rural area, needs generic stimulants, and has a straightforward ADHD presentation, Done can be cost-effective. At $99/month membership plus $50/month for generic mixed amphetamine salts with GoodRx, the total is $149/month. A single psychiatry visit in a major U.S. City commonly costs $350, $500 out of pocket. Done provides ongoing monthly medication management for less than the cost of one traditional visit.

When Done Is Not the Best Choice

Patients with insurance covering mental health benefits may find Talkiatry or a local psychiatry group cheaper after copays. Patients with complex psychiatric histories get better diagnostic workups from Tier 3 providers. Patients in states where Done is not licensed (check their website for current state availability) have no option regardless of price.

Done Reviews: What Patients Actually Report

Patient reviews of Done are mixed and follow a predictable pattern. Positive reviews tend to cluster around convenience and speed of initial evaluation. Negative reviews concentrate on three specific problems.

Common Positive Themes

• Evaluation completed within days rather than weeks
• Clinician communication via app messaging
• Prescriptions sent electronically to preferred pharmacy
• No insurance bureaucracy

Common Negative Themes

• Pharmacy shortages with no backup plan. Patients who cannot fill at one pharmacy report Done clinicians cannot easily transfer or adjust prescriptions across state lines.
• Difficulty discontinuing membership. Multiple Trustpilot and Reddit reports describe challenges canceling recurring billing.
• Limited clinical depth. Patients with comorbid anxiety or depression report Done clinicians declined to address those conditions and advised them to seek separate care, which adds cost.

What the Broader Telehealth Literature Shows

A 2022 JAMA Psychiatry study found that telehealth ADHD services increased stimulant prescribing rates significantly during the pandemic, raising questions about diagnostic rigor in some platforms [9]. The authors noted that "the rapid expansion of telehealth prescribing has outpaced the development of safeguards against inappropriate stimulant dispensing." That observation is not specific to Done, but it applies to the category.

A 2023 study in JAMA Network Open (N=3,001 adult ADHD patients) found that adults receiving ADHD treatment via telehealth had similar medication adherence rates at 6 months compared with in-person care (74.2% vs. 72.8%, P = 0.41), suggesting the format itself does not impair treatment continuity [10].

Is Done Worth It? A Clinical Perspective

Whether Done is worth it depends entirely on your situation. The membership fee structure rewards patients who stay long-term and tolerate generic medications. It penalizes patients who experience shortages, move states, or develop complications requiring specialist care.

Situations Where Done Makes Sense

• Uninsured or underinsured adults with a clear prior ADHD diagnosis seeking cost-effective medication management
• Adults in rural or underserved areas where psychiatry wait times exceed 3 to 6 months (the national median wait for a new psychiatric appointment is 25 days, but exceeds 60 days in many rural counties [11])
• Patients who have already completed a comprehensive evaluation elsewhere and need only ongoing Rx management

Situations Where Done Is Not the Right Fit

• First-time ADHD diagnosis in an adult with significant psychiatric comorbidities
• Patients who need stimulant medications and live in states with restrictive telemedicine prescribing rules
• Anyone with insurance that covers mental health at parity. Paying $1,200/year in membership fees when a $30 copay visit is available is a poor financial decision.

The Stimulant Shortage Problem Is Real

The DEA has maintained a reduced aggregate production quota for amphetamine salts since 2021. The FDA shortage database has listed amphetamine mixed salts products intermittently since late 2022 [1]. A telehealth-only provider cannot resolve this problem. Done cannot call a local compounding pharmacy or substitute a non-controlled alternative as easily as a traditional prescriber who has your full chart, your pharmacy history, and the ability to coordinate care in real time.

How Done Compares to Getting an ADHD Diagnosis Through Insurance

If you have health insurance with mental health parity coverage under the Mental Health Parity and Addiction Equity Act (MHPAEA), your insurer is required to cover outpatient psychiatry at the same level as medical/surgical benefits [12]. That means your stimulant prescription may cost $10, $40/month after a modest copay visit.

The math is direct. At $99/month in Done membership plus $50/month in medication, you spend $1,788/year. At a $30 copay visit every 3 months plus $20/month generic stimulant, you spend $360/year. The difference is $1,428. For many patients with insurance, the insurance route is dramatically cheaper.

The catch is access. Psychiatry wait times are long, primary care physicians vary in their comfort with ADHD diagnosis, and some insurers require pre-authorization for stimulants. If those barriers are real in your situation, Done may save time even if it costs more money.